¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"single cell protein"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
À̰ÍÀ» ¿øÇϼ̽À´Ï±î?
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
  • heart failure cell
    ½ÉºÎÀü¼¼Æ÷
  • HeLa cell
    Çï¶ó¼¼Æ÷
  • hair cell
    Åм¼Æ÷
  • helmet cell
    Åõ±¸¼¼Æ÷
  • helper cell
    µµ¿ò¼¼Æ÷, Á¶·Â¼¼Æ÷
  • helper cell activity
    µµ¿ò¼¼Æ÷Ȱ¼º
  • hematopoietic cell transplantation
    Á¶Ç÷¼¼Æ÷À̽Ä, Ç÷±¸Çü¼º¼¼Æ÷À̽Ä
  • hairy cell
    Åиð¾ç¼¼Æ÷
  • hairy cell leukemia
    Åм¼Æ÷¹éÇ÷º´
  • hemolytic plaque-forming cell
    ¿ëÇ÷ÆÇÇü¼º¼¼Æ÷, ¿ëÇ÷ÇöóÅ©Çü¼º¼¼Æ÷
  • hepatosplenic T-cell lymphoma
    °£ºñÀåT¼¼Æ÷¸²ÇÁÁ¾
  • heteroploid cell line
    À̼öü¼¼Æ÷°è
  • heterotrophic cell
    Á¾¼Ó¿µ¾ç¼¼Æ÷
  • high-threshold cell
    °í¹®Åΰª¼¼Æ÷
  • horizontal cell
    ¼öÆò¼¼Æ÷
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
  • lymphoid cell
    ¸²ÇÁ°è¼¼Æ÷, ¸²ÇÁ¸ð¾ç¼¼Æ÷
  • lymphokine-activated killer cell
    ¸²Æ÷Ä«ÀÎȰ¼º¼¼Æ÷µ¶¼º¼¼Æ÷
  • lymphopoietic cell
    ¸²ÇÁ±¸»ý¼º¼¼Æ÷
  • marrow cell
    °ñ¼ö¼¼Æ÷
  • mast cell
    ºñ¸¸¼¼Æ÷
  • mastoid air cell
    ²ÀÁö¹úÁý
  • matrix cell
    ±âÁú¼¼Æ÷, ÅйÙÅÁÁú¼¼Æ÷
  • memory cell
    ¸é¿ª±â¾ï¼¼Æ÷
  • Merkel cell-neurite complex
    Ã˰¢¼¼Æ÷½Å°æµ¹±âº¹ÇÕü
  • mesangial cell
    Ç÷°ü»çÀ̼¼Æ÷
  • mesenchymal cell
    Áß°£¿±¼¼Æ÷
  • mesothelial cell
    ÁßÇǼ¼Æ÷
  • microglial cell
    ¹Ì¼¼¾Æ±³¼¼Æ÷
  • mitotic cell
    ºÐ¿­±â¼¼Æ÷
  • mitral cell
    ½Â¸ð¼¼Æ÷
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
  • granular cell myoblastoma
    °ú¸³¼¼Æ÷±Ù¸ð¼¼ Æ÷Á¾(¡­á¬øàÐÉÙ½á¬øàðþ)
  • granular cell schwannoma
    °ú¸³¼¼Æ÷ ½´¹Ý¼¼Æ÷Á¾
  • granular cell tumo(u)r
    °ú¸³¼¼Æ÷ Á¾¾ç
  • granule cell
    °ú¸³¼¼Æ÷(¡­á¬øà).
  • granule cell
    °ú¸³¼¼Æ÷
  • granuloma,giant cell
    °Å´ë¼¼Æ÷¼º À°¾ÆÁ¾
  • granulopoietic cell
    °ú¸³__¶Ç÷¼¼Æ__
  • granulosa cell
    °ú¸³¸·¼¼Æ÷(¡­á¬øà).
  • granulosa cell carcinoma
    (³­¼Ò)°ú¸³¸·¼¼Æ÷ ¾ÏÁ¾(Õ°áµÎ¨í£Ø¯á¬øà ðþ).
  • granulosa cell tumor
    °ú¸³¸·¼¼Æ÷Á¾¾ç.
  • granulosa cell tumor
    °ú¸³¸·¼¼Æ÷Á¾¾ç
  • granulosa cell tumor
    °ú¸³¸·¼¼Æ÷Á¾¾ç
  • granulosa lutein cell
    °ú¸³ÃþȲü¼¼Æ÷, °ú¸³¸·È²Ã¼¼¼Æ÷(¡­Ø¯üÜô÷á¬øà).
  • granulosa lutein cell
    °ú¸³ÃþȲ(»ö)ü¼¼Æ÷
  • granulosa lutein cell
    °ú¸³ÃþȲü¼¼Æ÷, °ú¸³ ¸·È²Ã¼¼¼Æ÷(¡­Ø¯üÜô÷á¬øà).
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
  • aggressive basal cell carcinoma
    ħ½À ±âÀú¼¼Æ÷¾Ï(Ðñî¼á¬øàäß)
  • alpha cell
    ¾ËÆÄ¼¼Æ÷
  • alpha cell
    ¾ËÆÄ¼¼Æ÷(¡­á¬øà)
  • alpha cell tumor
    ¾ËÆÄ ¼¼Æ÷Á¾(¡­á¬øàðþ)
  • amacrine cell
    ¾Æ¸¶Å©¸° ¼¼Æ÷
  • amacrine cell
    ¹«Ãà»è¼¼Æ÷
  • ameboid cell
    ¾Æ¸Þ¹Ù¸ð¾ç¼¼Æ÷
  • analyzer for cell count
    ¼¼Æ÷¼öºÐ¼®±â
  • aneuploid cell
    À̼ö¼º¼¼Æ÷
  • angiotropic (intravascular) large cell lymphoma
    Ç÷°ü¿µ¾ç¼º(Ç÷°ü³»)´ë¼¼Æ÷¸²ÇÁÁ¾
  • anitschkow cell
    ¾Æ´ÏÄ¡ÄÚ¿ì¼¼Æ÷(¡­á¬øà)
  • annular elastotic giant cell granuloma
    ȯ»ó ź·Â ¼¶À¯¼º °Å´ë¼¼Æ÷ À°¾ÆÁ¾
  • anoxic cell
    ¹«»ê¼Ò¼¼Æ÷
  • anti-idiotypic T suppressor cell
    Ç×°³º°Æ¯ÀÌÇü ¾ïÁ¦T¼¼Æ÷
  • antibody dependent cell mediated cytotoxicity
    Ç×üÀÇÁ¸ ¼¼Æ÷¸Å°³ ¼¼Æ÷µ¶¼º.
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
  • protein modification
    ´Ü¹éÁú ¼ö½Ä(Ó±ÛÜòõáóãÞ)
  • protein overloading
    ´Ü¹éÁú°úºÎÇÏ(Ó±ÛÜòõΦݶùÃ)
  • protein processing
    ´Ü¹éÁú °¡°ø(Ó±ÛÜòõÊ¥Íï)
  • protein release factor
    ´Ü¹éÁú ¹æÃâÀÎÀÚ(Ó±ÛÜòõÛ¯õóì×í­)
  • protein score
    ´Ü¹éÁú°¡(Ó±ÛÜòõʤ)
  • protein sequencer
    ´Ü¹éÁú¼­¿­±â(Ó±ÛÜòõßíÖªÐï)
  • protein sequencing
    ´Ü¹éÁú ¼­¿­ °áÁ¤(Ó±ÛÜòõßí֪̽ïÒ)
  • protein-sparing action
    ´Ü¹éÁú Àý¾à ÀÛ¿ë(Ó±ÛÜòõï½å³íÂéÄ)
  • protein structure
    ´Ü¹éÁú ±¸Á¶(Ó±ÛÜòõϰðã)
  • protein synthesis
    ´Ü¹éÁú ÇÕ¼º(Ó±ÛÜòõùêà÷)
  • protein synthesis factor
    ´Ü¹éÁú ÇÕ¼ºÀÎÀÚ(Ó±ÛÜòõùêà÷ì×í­)
  • protein-synthesizing system
    ´Ü¹éÁú ÇÕ¼º(Ó±ÛÜòõùêà÷) ½Ã½ºÅÛ
  • protein turnover
    ´Ü¹éÁú Àüȯ(Ó±ÛÜòõï®üµ)
  • protein value
    ´Ü¹éÁú(Ó±ÛÜòõ)°ª
  • read-through protein
    ÆÇµ¶ ´Ü¹éÁú(÷÷ÔÁÓ±ÛÜòõ)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 19
SSCP single-stranded conformational polymorphism
SSD shaded surface display; single saturating dose; Social Security disability; source-skin distance; so...
ssDNA single-stranded DNA
ssRNA single-stranded ribonucleic acid
SV saphenous vein; sarcoma virus; satellite virus; selective vagotomy; semilunar valve; seminal vesicle...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 19
LAK cell lymphokine activated killer cell
M cell Mauthner cell
NK cell natural killer cell
P-cell Purkinje cell
TCRBCL T cell rich B cell lymphoma
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • multinucleated giant cell
    ´ÙÇÙ °Å´ë ¼¼Æ÷, °Å´ë ´ÙÇÙ ¼¼Æ÷, ´ÙÇÙ °Å¼¼Æ÷
  • multipolar nerve cell
    ¹µ ±Ø ½Å°æ ¼¼Æ÷, ´Ù±Ø ½Å°æ ¼¼Æ÷
  • muscle cell
    ±Ù ¼¼Æ÷
    ´Éµ¿ÀûÀ¸·Î ¼öÃ༺À» º¸ÀÌ´Â µ¿¹°Ã¼³»ÀÇ ¼¼Æ÷. ±ÙÀ° ¼¼Æ÷¶ó°íµµ ÇÑ´Ù. ±Ù Á¶Á÷À» ±¸¼ºÇÏ´Â °æ¿ì °¢°¢ÀÇ ±Ù ¼¼Æ÷´Â ÀϹÝÀûÀ¸·Î ¹æÃß»ó ¶Ç´Â ¼¶À¯»óÀ» ¶í´Ù. ÇØ¸éµ¿¹°Àº ±ÙÁ¶Á÷ÀÌ ¾øÀ¸³ª, ±Ô°¢ ÇØ¸é·ù¿¡¼­´Â üǥÀÇ ÆíÆò»óÇÇ ¼¼Æ÷°¡ ¾ó¸¶°£ ¼öÃ༺À» °¡Áö¸ç, üǥ ƯÈ÷ À¯Ãâ°ø ÁÖº¯¿¡ ¹Ì¿À»çÀÌÆ®¶ó°í ÇÏ´Â ±ä ¹æÃßÇüÀÇ ¼öÃ༺ ¼¼Æ÷°¡ Á¸ÀçÇÑ´Ù. ¶Ç ¼®È¸ ÇØ¸é·ùÀÇ ¼Ò°ø ¼¼Æ÷¿¡µµ ¼öÃ༺ÀÌ ÀÎÁ¤µÈ´Ù. À̵éÀº ¾î¶² Á¾·ùÀÇ ¿ø»ýµ¿¹° ¸ö Àüü¿¡ ³ªÅ¸³ª´Â ¼öÃ༺°ú ´õºÒ¾î ±Ù ¼¼Æ÷°¡ ³ªÅ¸³ª´Â ½ÃÀÛ ÇüÅ·Π°£ÁֵȴÙ. °­À嵿¹°ÀÇ Æú¸³Çü¿¡¼­´Â ¿Ü¹è¿± ¼¼Æ÷ Ãþ ¼Ó¿¡ ÀÖ´Â »óÇÇ ±Ù ¼¼Æ÷¿¡ ÁøÁ¤ÇÑ ±Ù¿ø¼¶À¯°¡ ÀÖ´Ù. À̰ÍÀº °¡Àå ÈçÈ÷ ÀÖ´Â ¿øÁÖ»óÇÇ ¼¼Æ÷, ÁïÁöÁö ¼¼Æ÷ÀÇ ±âÀúºÎ°¡ ¹æÃßÇüÀ¸·Î ´Ã¾î³ª¼­ ±× ºÎºÐ¿¡ ÇÑÇØ¼­ ±Ù¿ø¼¶À¯°¡ Á¸ÀçÇÏ´Â °ÍÀ¸·Î, üǥÀÇ »óÇÇ ¼¼Æ÷¿¡¼­ ±Ù¼¼Æ÷·Î ºÐÈ­ÇÏ´Â µµÁßÀÇ °ÍÀÌ´Ù. ÇØÆÄ¸® Çü¿¡¼­´Â ¹æÃßÇü ±Ù ¼¼Æ÷°¡ ¿Ï¼ºµÈ´Ù. ÆíÇüµ¿¹° À̻󿡼­´Â ÇDZÙÃþ, ±â°ü±Ù µî ºÐÈ­°¡ ÇöÀúÇÏ´Ù.
  • muscle-cell
    ±Ù ¼¼Æ÷
  • mycosis cell
    ¸¶ÀÌÄڽýº ¼¼Æ÷, Áø±Õ ¼¼Æ÷
    ¸¹Àº ºñÁ¤Çü ¸²ÇÁ°è ¼¼Æ÷ÀÇ Çϳª·Î¼­ °ú¿°»ö¼ºÀÇ ½ÉÇÑ È¸¼±»ó ÇÙÀ» °¡Áö°í ÀÖÀ¸¸ç ¿øÁ¶/À¯µµ ¼¼Æ÷ Ç¥ÇöÇüÀÇ T ¼¼Æ÷¿¡¼­ À¯·¡ÇÑ °ÍÀ¸·Î º¸ÀδÙ. ¿ë»ó Áø±ÕÁõ¿¡¼­ »óÇdzª ÆÄ¿ìÆ®¸®¾î
  • myoid cell
    ±ÙÀ°¾ç ¼¼Æ÷
  • natural kil1er cell
    ÀÚ¿¬ »ì¼¼Æ÷
    ¼±Ãµ¼º ¸é¿ªÀÇ Áß¿ä ÀÎÀÚ. ¼¼Æ÷ ³»¿¡ azuro
  • nerre cell body
    ½Å°æ¿øÃ¼, ½Å°æ ¼¼Æ÷ü
  • nerve cell
    ½Å°æ ¼¼Æ÷
    ´º·±¿¡¼­ µ¹±â¸¦ Á¦¿ÜÇÑ ºÎºÐ. ³ÐÀº Àǹ̷δ ´º·±°ú °°Àº ¶æÀ¸·Î ¾²ÀÌÁö¸¸ Á¼Àº Àǹ̷Π½Å°æ ¼¼Æ÷¸¦ ¼¼Æ÷ü
  • nerve cell layer
    ½Å°æ ¼¼Æ÷ Ãþ
  • neuroglial cell
    ½Å°æ¾Æ±³¼¼Æ÷, ½Å°æ ±³¼¼Æ÷
  • neuronal cell membrane
    ´º¿ì·± ¼¼Æ÷¸·
  • nh-cell ; °©»ó¼± ¹æ¿¡ ÀÖ´Â °ÍÀ¸·Î °¡Á¤µÇ´Â ½Å°æ È£¸£¸ó ¼¼Æ÷.

    Ni

    ´ÏÄÌ
    nickelÀÇ ¿ø¼Ò ±âÈ£.
  • Niemann Pick's cell
    ´Ï¸¸-ÇÇÅ© ¼¼Æ÷
    ·¹½ÃƾÀ» ´Ù·®À¸·Î ÇÔÀ¯ÇÏ´Â ¼¼Æ÷.
  • nociceptive dorsal horn cell
    Ä§ÇØ ¼ö¿ë¼º Èİ¢ ¼¼Æ÷, À¯ÇØ ¼ö¿ë¼º Èİ¢ ¼¼Æ÷
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 19
protein-N-pi-phosphohistidine - sugar phosphotransferase <enzyme> Enzyme II of the system; leve is the the IIb subunit from bacillus subtilis
Registry number: EC 2.7.1.69
Synonym: phph-phosphotransferase, phosphohistidinoprotein-hexose phosphotransferase, leve gene product, IIb(lev)
(26 Jun 1999)
protein N-terminal acetyltransferase <enzyme> From saccharmyces cerevisiae; encodes a catalytic subunit of an n-terminal acetyltransferase; ard1 and nat1 proteins are subunits of this enzyme
Registry number: EC 2.3.1.-
Synonym: nat1 gene protein, saccharomyces, yeast protein n-terminal acetyltransferase, n-terminal protein acetyltransferase, ard1 protein
(26 Jun 1999)
herpes simplex virus protein vmw65 Trans-acting protein that combines with host factors to induce immediate early gene transcription in herpes simplex virus.
(12 Dec 1998)
protein o-methyltransferase <enzyme> An enzyme that catalyses the transfer of methyl groups from s-adenosylmethionine to free carboxyl groups of a protein molecule forming methyl esters.
Chemical name: S-Adenosylmethionine:protein O-methyltransferase
Registry number: EC 2.1.1.-
(12 Dec 1998)
herpes simplex virus type 1 UL13 protein kinase <enzyme> Phosphorylates icp22 and involved in the accumulation of alpha and gamma mrnas and proteins in the infected cells; aa sequence has been determined
Registry number: EC 2.7.1.-
Synonym: ul13 protein kinase, hsv-1, hsv-1 ul13 protein, hsv-1 ul13 pk, u(l)13 protein kinase, protein kinase ul13
(26 Jun 1999)
protein p16 Product of the p16 tumour suppressor gene, that acts as cyclin-dependent kinase inhibitor of cdk4.
(12 Dec 1998)
protein p34cdc2 Phosphoprotein with protein kinase activity that functions in the g2/m phase transition of the cell cycle. It is the catalytic subunit of the maturation-promoting factor and complexes with both cyclin a and cyclin b in mammalian cells. The maximal activity of p34cdc2 is achieved when it is fully dephosphorylated. Protein p34cdc2, the product of the cdc2 gene in schizosaccharomyces pombe, should not be confused with the unrelated product of the cdc2 gene in saccharomyces cerevisiae that forms the large subunit of DNA polymerase III.
(12 Dec 1998)
protein p53 Nuclear phosphoprotein encoded by the p53 gene (genes, p53) whose normal function is to control cell proliferation. A mutant or absent p53 protein has been found in leukaemia, osteosarcoma, lung cancer, and colourectal cancer.
(12 Dec 1998)
protein phosphatases A class of enzymes that catalyze the dephosphorylation of specific phosphorylated proteins.
(05 Mar 2000)
protein processing, post-translational Any of various enzymically catalyzed post-translational modifications of peptides or proteins in the cell of origin. These modifications include carboxylation, hydroxylation, acetylation, phosphorylation, methylation, glycosylation, oxidation-reduction, degradation and lysis, peptide bond formation, and changes in molecular weight and electrophoretic motility.
(12 Dec 1998)
protein-proline kinase <enzyme> Phosphorylates synapsin i; phosphorylation takes place on serine 20, which is flanked by two proline molecules; heterodimer of p34(cdc2)/p58(cyclin a)
Registry number: EC 2.7.10.-
Synonym: proline-directed protein kinase
(26 Jun 1999)
protein quotient The number obtained by dividing the quantity of globulin of the blood plasma by the quantity of albumin.
Respiratory quotient (R.Q.), the steady state ratio of carbon dioxide produced by tissue metabolism to oxygen consumed in the same metabolism; for the whole body, normally about 0.82 under basal conditions; in the steady state, the respiratory quotient is equal to the respiratory exchange ratio.
Synonym: respiratory coefficient.
(05 Mar 2000)
protein S Nitrogenous organic compounds, containing more than about 100 amino acid residues, molecular weight 8,000-200,000, in vegetable and animal matter. Proteins yield amino acids on hydrolysis and are foods assimilated as amino acids and reconstructed in the protoplasm.
(12 Dec 1998)
Previous: protein processing, post-translational, protein-proline kinase, protein quotientNext: protein S, protein s deficiency, protein sequencingprotein S
Vitamin K dependent cofactor.
(18 Nov 1997)
protein s deficiency An autosomal dominant disorder showing decreased levels of plasma protein s antigen or activity, associated with venous thrombosis and pulmonary embolism. Protein s is a vitamin k-dependent plasma protein that inhibits blood clotting by serving as a cofactor for activated protein c (also a vitamin k-dependent protein), and the clinical manifestations of its deficiency are virtually identical to those of protein c deficiency. Treatment with heparin for acute thrombotic processes is usually followed by maintenance administration of coumarin drugs for the prevention of recurrent thrombosis.
(12 Dec 1998)
protein sequencing Determining the sequence of amino acids in a protein, a process carried out by automated techniques.
(14 Nov 1997)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 19
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 19
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 19
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 19
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 19
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 19
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 19
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 19
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 19
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 19
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 19
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 19
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 19
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 19
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 19
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 19
ÅëÇÕ°Ë»ö ¿Ï·á